Benefits of omega-3 fatty acid dietary supplementation on health-related quality of life in patients with meibomian gland dysfunction

Abstract

BackgroundWe assessed the impact of a dietary supplement based on the combination of omega-3 essential fatty acids and antioxidants on health-related quality of life in patients with meibomian gland dysfunction (MGD).MethodsPatients of either sex (aged 18–85 years) diagnosed with MGD according to criteria identified at a 2011 International Workshop on Meibomian Gland Dysfunction participated in this randomized, double-masked, placebo-controlled study. Group A patients (controls) received an oral placebo supplement and group B patients received the oral study supplement (Brudysec® 1.5 g; Brudy Laboratories, Barcelona, Spain). At baseline and at 3-month follow-up, the patients completed the 36-Item Short Form Health Survey questionnaire using a Spanish validated version. The Physical (PCS) and Mental (MCS) Component Summary scores were the main outcome variables.ResultsA total of 61 patients completed the study (group A, n=31; group B, n=30). There were no significant differences in PCS and MCS scores at baseline between the two study groups, but after 3 months of treatment, significantly higher mean PCS and MSC scores were observed in patients treated with the active omega-3 dietary supplement as compared with controls (mean [standard deviation] PCS score 53.33±5.57 versus 47.46±7.31, P=0.008; mean MCS score 54.60±5.64 versus 47.80±8.45, P=0.0005). Moreover, mean differences between values at 3 months as compared with baseline were statistically significant for patients in group B (PCS score 7.14±5.81, 95% confidence interval 4.97–9.31, P=0.000; MCS score 5.96±7.64, 95% confidence interval 3.10–8.81, P=0.0002), whereas mean differences in patients assigned to group A were not statistically significant.ConclusionDietary supplementation with a combination of omega-3 essential fatty acids and antioxidants had a significant beneficial effect on HRQoL (health-related quality of life) in patients with MGD.

A comparison of the self‐reported dry eye practices of New Zealand optometrists and ophthalmologists

“…A similar trend was evident for increasing recommendations of omega‐3 essential fatty acid intake with increasing severity, with almost four out of five practitioners indicating they would recommend this treatment for severe dry eye. Traditionally, enhancing omega‐3 essential fatty acid intake has been considered beneficial for improving cardiovascular health and reducing inflammation in rheumatoid arthritis; however, recent epidemiological studies and clinical trials have also reported promising findings in relation to treating DED . Further research is required to clarify specific factors such as optimal treatment duration, optimum dosage, and/or possible benefits of adjunct omega‐6 essential fatty acid intake, suggesting potential for expansion of the evidence base in this area of practice.…”

Prospective Trial of Intense Pulsed Light for the Treatment of Meibomian Gland Dysfunction

“…12 Current management paradigms range from self-administered or practitioner-administered treatments with artificial tears, heat application, and manual gland expression 13,14 (often providing only transient relief) to therapies that aim to restore the natural balance of lipids within the meibum. Such therapies include omega-3 supplementation, 15 topical antibiotics to lessen the local bacterial load, oral tetracyclines to reduce the level of pro-inflammatory cytokines, 16 corticosteroids, or topical cyclosporine. 3 Despite the broad range of therapies available, MGD management is commonly considered unsatisfactory by both clinicians and affected patients, and alternative options for management are continually sought.…”

Evaluation of the efficacy of optimal pulsed technology treatment in patients with cataract and Meibomian gland dysfunction in the perioperative period

“…The purpose of treating MGD is to improve the secretion function of the meibomian glands, to improve the stability of the tear film, and to alleviate the symptoms of DE in patients. The current treatment methods for MGD [26] include: (1) physical therapy: eyelid cleaning, hot compress, Meibomian Gland Expression (MGX), acupuncture, Lipi-Flow meibomian gland heat pulsation therapy, OPT treatment, and correcting the patient's blinking habits;…”